- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03864900
Efficacy of a Health Belief Model Based Intervention for Anticoagulation Adherence
Efficacy of a Health Belief Model Based Intervention for Anticoagulation Adherence in Patients With Atrial Fibrillation: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND: Inconsistent anticoagulation therapy in AF patients is associated with a higher risk of stroke and abnormal bleeding. However, control of oral anticoagulation therapy in AF patients has been frequently reported as inadequate. Few theoretical based interventions have been tested for enhancing medication adherence in this population. Previous studies showed that the health belief model may offer some advantage over other behavior change theories for enhancing medication adherence in adult with chronic conditions.
PURPOSE: The purpose of the study is to investigate the efficacy of a health belief model based self-management of oral anticoagulant therapy intervention on the outcome of medication adherence and the mediators of knowledge, professional support, health belief, and self-efficacy in patients treated with oral anticoagulants for atrial fibrillation.
METHODS: The study is a randomized clinical trial with repeated measurements. A convenient sample of 72 adults who were treated with anticoagulants for atrial fibrillation was recruited from two teaching hospitals in northern Taiwan. Participants were randomly assigned 1:1 to either the control group (n = 36) or the intervention group (n = 36) after completion of baseline questionnaires. Allocation was balanced by site by using a minimization method. The health belief model based self-management intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls. Participants in the control group received regular medication education, 10-minute individual instruction for health knowledge and six follow-up telephone calls for concerning health. Data were collected at baseline, third month, and sixth month in both groups, by using self-administered questionnaires. The investigator administered the study questionnaire after obtaining informed consent from each subject. The data collection took place at the waiting areas outside the outpatient clinics during the patients' visits to the clinics. For subjects who were unable to read the questionnaire due to vision or other problems, the investigator read each question to help them complete the questionnaire. The instruments include the Atrial Fibrillation Knowledge Scale, Satisfaction Scale about Service and Warfarin Treatment, Belief About Anticoagulation Survey, and Self-Efficacy for Appropriate Medication Use Scale.
DATA ANALYSIS: Data were analyzed using the Statistical Package for Social Sciences 20.0 (SPSS, Inc., Chicago, IL, USA). Descriptive analyses were used to describe study variables. Independent t-tests and one-way analysis of variance (ANOVA) were performed to analyze the baseline equivalent between study groups. The generalized estimating equations were used to analyze the efficacy of the intervention for enhancing knowledge, knowledge, perceived benefits, perceived barriers, self-efficacy, and adherence to anticoagulant therapies in patients treated with oral anticoagulants for atrial fibrillation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 116
- Taipei Medical University WanFang Hospital
-
-
Taipei
-
Taipei county, Taipei, Taiwan, 235
- Taipei Medical University Shuang Ho Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥ 20 years of age
- fluent in Mandarin or Taiwanese
- diagnosed with AF
- treated with warfarin or NOACs for anticoagulation.
Exclusion Criteria:
- diagnosed with psychological diseases
- diagnosed with uncontrolled hypertension
- diagnosed with the New York Heart Association (NYHA) grade VI heart failure
- implanted with a cardiac pacemaker
- had cardiac surgery in the past three months
- hospitalized for AF in the past three months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: The intervention group
The medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
|
The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
|
|
NO_INTERVENTION: The control group
Participants in the control group received regular medication education, 10-minute individual instruction for health knowledge and six follow-up telephone calls for concerning health.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Short-form Adherence to Refills and Medications Scale (ARMS)
Time Frame: baseline (T1), 12th week (T2), and 24th week (T3) follow-ups.
|
There are seven items in the scale.
Subjects were asked to indicate how often they actually miss taking their anticoagulants in each item on a 4-point Likert scale (1_ none of the time to 4_ all of the time).
The total score of the 7 items represents the scale score, with a possible range of 7 to 28.
A higher score indicates worse adherence to anticoagulation treatment.
|
baseline (T1), 12th week (T2), and 24th week (T3) follow-ups.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Knowledge of Warfarin Anticoagulation Treatment Scale
Time Frame: baseline (T1), 12th week (T2), and 24th week (T3) follow-ups.
|
The 11-item scale covers four areas of warfarin treatment knowledge: administration (e.g., dose, color, and route of administration), interaction with foods, interaction with other drugs, and side effects.
There are five choices for each item, and only one of the choices is correct (scored 1).
The total score of the 11 items represents the scale score, with a possible range of 0 to 11.
Higher scores indicate higher levels of understanding of warfarin treatment.
The scale was also modified to measure the NOACs treatment knowledge.
To facilitate analysis and comparison, the score of each scale was converted to a scale of 0 to 100 (actual score/possible maximum score x 100).
|
baseline (T1), 12th week (T2), and 24th week (T3) follow-ups.
|
|
The Perceived Benefits Subscale of the Beliefs About Anticoagulation Survey (BAAS)
Time Frame: baseline (T1), 12th week (T2), and 24th week (T3) follow-ups.
|
The subscale covers 5 potential benefits of taking anticoagulation, including lessening the risk of having a stroke, lowering the chance of being hospitalized, feeling healthier, improving quality of life, and worrying less about the disease.
For each item, the subjects indicated their levels of agreement on a 5-point Likert scale (from 1_ strongly disagree to 5_ strongly agree).
The potential scores range from 5 to 25 points, with higher scores indicating higher levels of perceived benefits associated with taking anticoagulation.
|
baseline (T1), 12th week (T2), and 24th week (T3) follow-ups.
|
|
The Concerns About Anticoagulation Therapy Scale
Time Frame: baseline (T1), 12th week (T2), and 24th week (T3) follow-ups.
|
The scale lists ten potential concerns, including drug interactions, forgetting to take anticoagulants, side effects, hospital visits, diet interactions, activity restrictions, impact on work, not helpful, and difficulty of following instructions.
The subjects were asked to indicate all concerns that apply to them.
Each concern was scored 1.
The potential scores range from 0 to 10, with higher scores indicating more concerns.
|
baseline (T1), 12th week (T2), and 24th week (T3) follow-ups.
|
|
The Self-efficacy for Appropriate Medication Use Scale (SEAMS)
Time Frame: baseline (T1), 12th week (T2), and 24th week (T3) follow-ups.
|
The 13-item scale covers two dimensions of self-efficacy: for taking medications under difficult circumstances and for taking medications under uncertain or changing circumstances.
For each item, the subjects indicated their level of confidence about taking medications correctly under a specific circumstance on a three-point response scale (1 _ not confident, 2 _ somewhat confident, and 3 _ very confident).
The potential scores range from 13 to 39, with high scores indicating higher levels of self-efficacy for appropriate anticoagulant use.
|
baseline (T1), 12th week (T2), and 24th week (T3) follow-ups.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Satisfaction Scale About Service and Warfarin Treatment (SSWT)
Time Frame: baseline (T1), 12th week (T2), and 24th week (T3) follow-ups
|
The original scale includes seven positive statements about the services and warfarin treatment.
In the current study, the term of warfarin was replaced with anticoagulants.
The item 5 (regarding INR monitoring) in the original scale was deleted as it only applies to patients treated with warfarin.
Therefore, there were only six items used in the current study.
For each item, the subjects indicated their levels of agreement on a 5-point Likert scale (from 0_ strongly disagree to 4_ strongly agree).
The total score of the 6 items represents the scale score, with a possible range of 0 to 24.
Higher scores indicate higher levels of satisfaction about service and warfarin treatment.
|
baseline (T1), 12th week (T2), and 24th week (T3) follow-ups
|
Collaborators and Investigators
Publications and helpful links
General Publications
- January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28. No abstract available. Erratum In: J Am Coll Cardiol. 2014 Dec 2;64(21):2305-7.
- Chiang CE, Wu TJ, Ueng KC, Chao TF, Chang KC, Wang CC, Lin YJ, Yin WH, Kuo JY, Lin WS, Tsai CT, Liu YB, Lee KT, Lin LJ, Lin LY, Wang KL, Chen YJ, Chen MC, Cheng CC, Wen MS, Chen WJ, Chen JH, Lai WT, Chiou CW, Lin JL, Yeh SJ, Chen SA. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc. 2016 Nov;115(11):893-952. doi: 10.1016/j.jfma.2016.10.005. Epub 2016 Nov 24.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Alexandru Popescu B, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Rev Esp Cardiol (Engl Ed). 2017 Jan;70(1):50. doi: 10.1016/j.rec.2016.11.033. No abstract available. Erratum In: Rev Esp Cardiol (Engl Ed). 2017 Nov;70(11):1031. English, Spanish.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 201505054
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anticoagulants
-
University Hospital, GhentCompletedHemodialysis Complication | AnticoagulantsBelgium
-
University of North Carolina, Chapel HillCompleted
-
I.M. Sechenov First Moscow State Medical UniversityCompleted
-
IRCCS Policlinico S. DonatoNot yet recruitingSelf Efficacy | Self Confidence | Anticoagulants
-
Legacy Health SystemPacific UniversityUnknownExtracorporeal Membrane Oxygenation Complication | AnticoagulantsUnited States
-
Fondation Ophtalmologique Adolphe de RothschildCompletedPer-procedural Concentrations of Oral AnticoagulantsFrance
-
University College, LondonActive, not recruitingDirect Oral Anticoagulants (DOACs)United Kingdom
-
St. Joseph's Healthcare HamiltonCanadian Institutes of Health Research (CIHR); Hamilton Health Sciences Corporation and other collaboratorsCompleted
-
University Hospital TuebingenHeart and Diabetes Center North Rhine-WestphaliaCompletedAnticoagulation With Direct Oral Anticoagulants
-
University Hospital TuebingenHeart and Diabetes Center North Rhine-WestphaliaCompletedAnticoagulation With Direct Oral Anticoagulants
Clinical Trials on The medication adherence intervention
-
Massachusetts General HospitalRecruitingStroke | Ischemic Stroke | Intracerebral Haemorrhage | TIA (Transient Ischemic Attack)United States
-
University of North Carolina, Chapel HillMedical University of South Carolina; National Institute of Mental Health (NIMH) and other collaboratorsCompletedHIV/AIDS | Medication Adherence | Hiv | Sexual Behavior | Sexually Transmitted Infections (Not HIV or Hepatitis)United States
-
The Hong Kong Polytechnic UniversityCastle Peak Hospital; Kwai Chung Hospital, Hong KongCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform DisorderHong Kong
-
University of Missouri-ColumbiaCompletedHypercholesterolemia | Medication AdherenceUnited States
-
University of PennsylvaniaActive, not recruitingHypertension and HyperlipidemiaUnited States
-
University Hospital, MontpellierUnknown
-
Rhode Island HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
University of WashingtonAmerican Association of Diabetes EducatorsUnknown
-
University Hospital, ToulouseCompleted
-
Collabree AGUniversity Hospital, Basel, SwitzerlandCompletedHypertension | Medication AdherenceSwitzerland